Source: Annual Congress 2006 - Recent update on asthma treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Pascoe, L. J. Knowles, M. Glasbrenner, T. Duvauchelle, R. Fuhr, L. J. Brookman (Horsham, United Kingdom; Basel, Switzerland; Paris, France; Berlin, Germany). Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma. Eur Respir J 2006; 28: Suppl. 50, 1238

Member's Comments

No comment yet.

Related content which might interest you: 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Safety and tolerability of high-dose formoterol via aerolizer and salbutamol via MDI in patients with mild-to-moderate COPD Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003 Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009 A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD Source: Eur Respir J 2014; 43: 763-772 Year: 2014 Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001 Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Cardiac safety of indacaterol, a novel once-daily bronchodilator, in COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004 Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Efficacy of inhaled ciclesonide compared with oral prednisolone in the treatment of asthma exacerbations Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006 Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001 Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006 Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Source: Eur Respir J 2011; 37: 273 Year: 2011 Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Comparison between zafirlukast and two fluticasone doses in asthma treatment Source: Eur Respir J 2005; 26: Suppl. 49, 368s Year: 2005